Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

The purpose of this clinical trial is to learn if allogeneic cord blood-derived CAR-T cell drug works to treat Multiple Myeloma (MM) including Bone-related extramedullary (EMB) disease and extramedullary extraosseous disease(EME) in adults. It will also learn about the safety of the allogeneic cord blood-derived CAR-T cell drug. The main questions it aims to answer are: 1. What adverse events occur and the incidence rate of DLTs within 28 days and UCAR-T-related AEs within 28 days after the allogeneic cord blood-derived CAR-T cell injection for multiple myeloma (MM)? 2. Which dose level is th

Trial Details

NCT ID
NCT07139509
Phase
PHASE1
Sponsor
Xi'an No.3 Hospital
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells
Locations (sample)
  • Xi’an, Shanxi, China|35.99785,113.52486

Key Eligibility Criteria

  • Aged 18 to 75 years (inclusive of boundary values), with no limitation on gender;
  • Diagnosed with multiple myeloma in accordance with the "Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (2022 Revision)" :
  • Bone marrow monoclonal plasma cell percentage ≥10% and/or histopathological evidence of plasmacytoma; and presence of at least one of the following…
  • SLiM refers to:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →